Navigation Links
Approval Of Boston Scientific's Watchman Device Will Support Rapid Growth In The Global Heart Defect Closure Device Market

TORONTO, June 12, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the anticipated Food and Drug Administration (FDA) approval of Boston Scientific's WATCHMAN device will drive rapid growth in the market for global heart defect closure devices.


Although a number of epicardial left arterial appendage (LAA) closure devices are available worldwide, the WATCHMAN device will represent the first FDA-approved endocardial LAA device when it enters the market in the latter half of 2013. Approval is more difficult to obtain for endocardial devices because they are placed directly inside the LAA opening of the heart, whereas epicardial devices function from outside of the heart.

"Endocardial LAA closure devices have huge global market potential," said MRG Senior Analyst Sean Messenger. "These devices will expand the eligible patient pool for LAA closure because they will be approved for stand-alone use in the US, as they are in Europe. By contrast, the majority of epicardial devices are only approved for concomitant use when patients are undergoing open cardiac surgery for another condition. Physicians are also familiar with endocardial devices given that interventional cardiologists have been using very similar devices for many years."

Market growth will be particularly strong in the US, where clinical trial results from the PROTECT-AF and PREVAIL studies will support device approval and encourage physician adoption of the WATCHMAN device. FDA approval is also highly regarded in Europe, and as a result, the WATCHMAN device will see strong uptake in this market as well. The device will not enter the Japanese market until it has been well-established in the US and Europe, although market growth is expected to be strong once endocardial LAA devices enter this space.

St. Jude Medical, the current global leader of the heart defect closure device market, is also expected to eventually enter the endocardial LAA closure device segment; the company recently began a US-based trial for a device in this space. This is not expected to occur for some time, however, and Boston Scientific will enjoy a first-to-market advantage, monopolizing this market for a number of years.   

Millennium Research Group's Global Markets for Heart Defect Closure Devices 2013 report includes unit, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for congenital heart defect, patent foramen ovale (PFO) and LAA closure devices in the United States, France, Germany, Italy, the United Kingdom and Japan.

About Millennium Research Group
Millennium Research Group (, a Decision Resources Group company (, is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group

Alex Jablokow
Millennium Research Group

SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ohr Pharmaceutical Announces Approval for Listing on NASDAQ
2. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
3. The Leukemia & Lymphoma Society Applauds FDAs Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
4. Cochlear Americas Receives FDA Approval for the First and Only Ear Level Accessory for Waterproof Hearing with Cochlear Implants
5. Approval for One Neuropathic Pain Indication is Sufficient to Support Physician Prescribing and Payer Reimbursement Across Multiple Neuropathic Pain Populations
6. ReproCELL Inc. Announces Approval for Listing on the Osaka Stock Exchange JASDAQ Market Growth
7. 3SBio Inc. Announces Shareholders Approval of the Amended Merger Agreement
8. Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico
9. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
10. MiEs PET SCINTRON Receives FDA Approval
11. TWi Pharmaceuticals Announces Tentative ANDA Approval for Guanfacine Hydrochloride Extended-Release Tablets
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):